Executive Director, Basser Center for BRCA and Basser Professor in Oncology
Abramson Cancer Center
University of Pennsylvania
For demonstrating that genetic testing for high penetrance cancer susceptibility genes can improve risk assessment, inform appropriate risk reduction strategies, and be used to develop targeted therapeutics, and for applying this paradigm to genetic information across the pathogenicity and penetrance spectrum. An international expert in the translation of genetic testing for cancer susceptibility, she has revolutionized the clinical care of patients in the areas of cancer prevention, early detection, and treatment and has shown that prophylactic salpingo-oophorectomy decreases the risk of breast and ovarian cancer and is associated with improved survival in BRCA1 and BRCA2 mutation carriers. She has also been instrumental in the development of PARP inhibitors and immunologic therapies as potential treatments for BRCA1/2 mutation-associated cancers of multiple types, including breast, pancreas, and ovarian cancer.
This award recognizes five prominent and influential female cancer researchers who have made outstanding contributions to the fundamental understanding, prevention, and/or treatment of breast or any form of gynecologic cancer. To learn more, please visit the press release.